花园生物：12月15日召开董事会会议

Group 1 - The core viewpoint of the news is that Huayuan Bio announced a board meeting to discuss amendments to the company's articles of association and provided insights into its revenue composition for 2024 [1][2] - Huayuan Bio's revenue composition for the year 2024 is as follows: vitamins account for 65.08% and the pharmaceutical manufacturing industry accounts for 34.92% [1] - As of the latest report, Huayuan Bio has a market capitalization of 8.1 billion yuan [2] Group 2 - The news highlights concerns regarding the financial practices of related parties associated with Huayuan Bio, with allegations of mismanagement leading to significant financial losses [2] - There are ongoing inquiries from shareholders regarding the financial status and transparency of the company, particularly in light of the reported sales figures and the potential for delisting [2]